Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993707 · ClinicalTrials.gov registry record · Phase 2
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)
A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Turino, Gerard, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 3
- Study locations
NCT00993707 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Turino, Gerard, M.D.. The registered enrollment target is 11 participants, below the 651-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00993707, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Turino, Gerard, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to evaluate the safety of administering repeated doses of CTX-100 (formerly ETX-100) to subjects with smoking-related chronic obstructive pulmonary disease.
Conditions Studied
Interventions
- DRUG CTX-100 (formerly ETX-100) (hyaluronic acid)
Study Locations (3)
New York
- VA Harbor Medical Center - New York
- St. Luke's-Roosevelt Hospital Center - New York
Arizona
- Arizona Research Associates - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00993707
The ClinicalTrials.gov registry entry for NCT00993707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 651-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (98% lower). The listed sponsor is Turino, Gerard, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 1 intervention - of which CTX-100 (formerly ETX-100) (hyaluronic acid) is the first listed.
NCT00993707 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT00993707 about?
NCT00993707 is a clinical study titled "Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)". The purpose of the study is to evaluate the safety of administering repeated doses of CTX-100 (formerly ETX-100) to subjects with smoking-related chronic obstructive pulmonary disease.
What is the current status of trial NCT00993707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2010-11. Estimated completion is 2013-03.
What conditions does trial NCT00993707 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT00993707?
The interventions under investigation include: CTX-100 (formerly ETX-100) (hyaluronic acid) (DRUG).
Who is sponsoring clinical trial NCT00993707?
This trial is sponsored by Turino, Gerard, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00993707 being conducted?
This trial has 3 study locations across Arizona, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 2
-
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
COMPLETED · Phase 2
-
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
-
Sodium Pyruvate Therapy in COPD Patients
COMPLETED · Phase 2
-
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.